EFFECTIVE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE AND DEPRESSIVE DISORDERS WITH NOOTROPICS DRUG PANTOGAM ACTIV
https://doi.org/10.20514/2226-6704-2016-6-1-54-62
Abstract
We investigate the efficiency of the inclusion nootropic drug Pantogam Activ in the complex therapy of 82 patients with heart failure, ischemic heart diseases, anxiety and depressive disorders. It was shown that an 8-week treatment with Pantogam Activ in most patients is accompanied by a significant reduction of anxiety and depressive disorders, increase exercise tolerance, improved autonomic regulation of heart function and decrease the frequency of supraventricular and ventricular arrhythmias, which is accompanied by a marked improvement in the quality of life.
About the Authors
A. P. Baranov
Department of Internal Medicine and medical radiation diagnosis Pirogov Russian National Research Medical University, Moscow, Russia
Russian Federation
Russian Federation
A. V. Strutynsky
Department of Internal Medicine and medical radiation diagnosis Pirogov Russian National Research Medical University, Moscow, Russia
Russian Federation
Russian Federation
O. Sh. Oynotkinova
Department of Internal Medicine and medical radiation diagnosis Pirogov Russian National Research Medical University, Moscow, Russia
Russian Federation
Russian Federation
E. V. Gorbacheva
Department of Internal Medicine and medical radiation diagnosis Pirogov Russian National Research Medical University, Moscow, Russia
Russian Federation
Russian Federation
V. V. Trishina
Department of Internal Medicine and medical radiation diagnosis Pirogov Russian National Research Medical University, Moscow, Russia
Russian Federation
Russian Federation
A. S. Gusev-Scherbakov
Department of Internal Medicine and medical radiation diagnosis Pirogov Russian National Research Medical University, Moscow, Russia
Russian Federation
Russian Federation
J. J. Golubev
Department of Internal Medicine and medical radiation diagnosis Pirogov Russian National Research Medical University, Moscow, Russia
Russian Federation
Russian Federation
References
1. Ageev F.T. et al. Patients with chronic heart failure in the Russian ambulatory practice : . contingent features, diagnosis and treatment (studies AGE -O- CHF) . Heart failure. 2004; 5(1): 4–7.
2. Bakaev R.G. "Features of the formation , progression and results of long-term drug therapy of CHF in patients with coronary artery disease , myocardial infarction" Author. diss . Doctor . M., 2010; 50 с.
3. Buryachkovskaya L.I. Activation of platelets and inflammatory markers in patients with coronary disease depression heart. Therapeutic Archives. 2006; 78(10): 9–14.
4. Vasyuk Y.A., Dovzhenko T.V. , Shkolnik E.L. Depression in ischemic CHF. Heart failure. 2004; 5(3): 141–147.
5. 5 Vasyuk Y.A., Dovzhenko T.V. Features pathogenetic relationship depression , and cardiovascular diseases. Mental disorders in general medicine. 2007; 2(1): 1–11.
6. Gaeva DB Influence of drug correction of depression on quality of life of patients with essential hypertension complicated by heart failure . Author. diss . cand . medical. Sciences . M. 2011; 27 с.
7. Kovalev G.I., Starikova N.A. Pantogam asset: the mechanism of pharmacological action . Russian Medical Journal. 2010; 21: 2–4.
8. Medvedev V.E., Albantova K.A. Pantogam asset in the treatment of neurotic, stress-related and somatoform disorders in patients with cardiac hospital . Mental disorders in general medicine. 2009; 2: 40–43.
9. Oganov R.G. Depression in cardiology: more than a risk factor. Ross. Nat. Congress of Cardiology: Materials of Congress. М. 2003: 1–4.
10. Pantogam and Pantogam asset. Clinical application and basic research. Ed. V.M. Kopelevich. M.: Triad Farm, 2009.
11. Petrov N.N., Kutuzova A.E. Psychosomatic aspects of chronic heart failure . Mental disorders in general medicine. 2011; 2: 23–28.
12. Poghosova G.V. Depression new risk factor for coronary heart disease and coronary death predictor. Cardiology. 2002; 4: 86–91.
13. Poghosova G.V. Depression in patients with coronary heart disease and its treatment opportunities. Consilium Medicum. 2002; 4(5): 22–26.
14. Chazov E.I. et al. COORDINATE Program (clinico-epidemiological study of depression program in cardiology practice in patients with hypertension and coronary heart disease): results of a multicenter study of the therapeutic. Ter. Arch. 2006; 78(4): 38–44.
15. Yankovskaya V.L. Depression and heart failure. Young scientist. 2014; 17: 223-227.
16. Allman Е., Berry D., Nasir L. Depression and coping in heart failure patients: a review of the literature. J. Cardiovasc. Nurs. 2009; 24(2): 106–117.
17. Blumenthal J.A., Lett H.S., Babyak M.A. et al. Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet 2003; 362: 604-609.
18. Carney R. Depression, Heart Rate Variability, and Acute Myocardial Infarction. Circulation. 2001; 104: 2024–2028.
19. LeMaitre J.P. Change in circulating cytokines after 2 forms of exercise training in chronic stable heart failure. Am. Heart. J. 2004; 47: 100–105.
20. Rutledge Т. et al. Depression in Heart Failure. A Meta-Analytic Review of Prevalence, Intervention Effects, and Associations With Clinical Outcomes. J. Am. Coll. Cardiol. 2006; 48(8): 1527–1537.
21. Junger М. Depression increasingly predicts mortality in the course of congestive heart failure. Eur. J. Heart Fail. 2005; 7: 261–267.
22. Johnson T.J. Depression predicts repeated heart failure hospitalizations. J. Card. Fail. 2012; 18(3): 246–252.
Review
For citations:
Baranov A.P., Strutynsky A.V., Oynotkinova O.Sh., Gorbacheva E.V., Trishina V.V., Gusev-Scherbakov A.S., Golubev J.J. EFFECTIVE TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE AND DEPRESSIVE DISORDERS WITH NOOTROPICS DRUG PANTOGAM ACTIV. The Russian Archives of Internal Medicine. 2016;6(1):54-62. (In Russ.) https://doi.org/10.20514/2226-6704-2016-6-1-54-62
Views:
4471
Email this article 